For Doctors in a Hurry
- Researchers investigated how biomarker changes and baseline levels predict kidney response to belimumab in 446 patients with active lupus nephritis.
- This Phase 3 trial randomized 446 adults to receive either 10 mg/kg of intravenous belimumab or placebo alongside standard immunosuppressive therapies.
- Belimumab treatment led to greater reductions in anti-double-stranded DNA antibodies and B cells compared to placebo over 104 weeks.
- The researchers identified that high baseline anti-complement 1q antibodies and early decreases in proteinuria predict favorable kidney responses to belimumab.
- Clinicians can monitor early immunoglobulin changes to better assess the likelihood of treatment success in patients receiving belimumab for lupus.
Predictive challenges in the management of lupus nephritis
Lupus nephritis remains a primary driver of long-term morbidity in systemic lupus erythematosus, frequently progressing to end-stage renal disease if initial induction therapy fails to achieve a complete renal response [1, 2]. While conventional regimens utilizing mycophenolate mofetil or cyclophosphamide are established standards, a significant proportion of patients remain refractory to these treatments or experience severe drug-induced toxicities [3, 4]. The integration of B-cell targeting biologics into multitarget induction protocols has recently expanded the therapeutic landscape, with clinical evidence suggesting improved renal outcomes and a reduced risk of flares [5, 6, 7]. However, the inherent heterogeneity of the disease means that clinical response to these agents remains variable across different patient populations [8, 9]. To address this variability, a recent analysis of Phase 3 trial data examines how specific immunological markers might help clinicians identify the patients most likely to benefit from adding belimumab to standard induction therapy.
Trial design and patient characteristics
The BLISS-LN study was a Phase 3 trial designed to evaluate the efficacy and safety of adding belimumab to standard-of-care regimens for adults with active lupus nephritis. The researchers enrolled a total of 446 patients, all of whom were randomized to receive either intravenous belimumab at a dosage of 10 mg/kg or a placebo, administered alongside standard immunosuppressive therapy. To reflect real-world clinical practice, the trial structure accounted for variations in standard induction and maintenance protocols. Within the belimumab treatment arm, 59 patients received cyclophosphamide as initial therapy followed by azathioprine, while 164 patients received mycophenolate mofetil followed by mycophenolate mofetil maintenance. The placebo arm was balanced identically, with 59 patients receiving the cyclophosphamide regimen and 164 patients receiving the mycophenolate mofetil protocol. This distribution allowed the authors to assess whether the effects of belimumab remained consistent across different background treatments. The primary observation period for this analysis extended through Week 104, a timeframe intended to capture durable clinical responses in a disease characterized by chronic inflammation and potential relapse. At this final time point, approximately 50 to 60 percent of the original 446 patients had available treatment data for the assessment of biomarker responses and kidney outcomes. This longitudinal data set enabled the researchers to utilize logistic regression models, a statistical method used to predict the probability of an outcome based on prior variables, to evaluate how baseline levels of immunoglobulins, B-cell subsets, and early changes in proteinuria might serve as indicators of therapeutic success.
Long-term immunological shifts with belimumab
The researchers conducted a longitudinal assessment of biomarker responses through Week 104, evaluating absolute and percentage changes from baseline in several key immunological markers. These included immunoglobulins, anti-double-stranded DNA (anti-dsDNA) antibodies, and anti-C1q antibodies, which are autoantibodies strongly associated with active renal disease and poor renal outcomes. The study also tracked levels of complement components C3 and C4, alongside total CD19+ B cells and various B-cell subsets. By the end of the 104-week period, patients treated with belimumab demonstrated numerically greater percentage reductions in IgA, IgM, and anti-dsDNA antibodies compared with those in the placebo group. Furthermore, belimumab was associated with numerically greater percentage reductions in plasmablasts, the immature B cells responsible for the rapid production of pathogenic antibodies during an immune response. Beyond the reduction of autoantibodies and their precursors, the treatment significantly influenced complement activity and B-cell populations. Belimumab was associated with greater increases in C3 and C4 levels compared with placebo, a finding that typically suggests a reduction in the consumption of these proteins and a corresponding decrease in systemic inflammation. The therapy also reduced total CD19+ B cells and naïve B cells, mature B cells that have not yet encountered a specific antigen, relative to the placebo arm. These immunological shifts remained generally consistent across the overall study population and within both induction subgroups, regardless of whether patients received cyclophosphamide or mycophenolate mofetil as their initial standard therapy. For the practicing nephrologist or rheumatologist, this consistency indicates that the biological impact of belimumab on B-cell mediated pathways is robust and predictable across common lupus nephritis treatment regimens.
Baseline and early markers of clinical response
To identify which patients are most likely to benefit from the addition of belimumab to standard therapy, the researchers utilized post hoc logistic regression models to determine which specific variables at the start of treatment could predict a successful kidney response by Week 104. The analysis revealed that several immunological characteristics at baseline were associated with improved clinical outcomes. Specifically, high baseline levels of IgA and anti-C1q antibodies, autoantibodies frequently linked to severe renal inflammation, served as significant predictors of treatment success. Furthermore, the cellular profile of patients at the time of enrollment provided additional prognostic value, as high baseline levels of naïve B cells and low baseline plasmablasts were also identified as indicators of a favorable kidney response to the therapy. Beyond baseline characteristics, the study identified early dynamic changes in biomarkers that correlated with long-term efficacy. Clinicians may find prognostic value in monitoring shifts during the initial phases of treatment, as early decreases from baseline in levels of IgA and IgM were associated with a positive kidney response at the two-year mark. Perhaps most critically for clinical practice, the researchers found that early decreases in the urinary protein to creatinine ratio, a standard measure of protein loss in the urine, were predictive of success at Week 104. These findings suggest that both the initial serological profile and the rapid stabilization of proteinuria may help physicians tailor the use of belimumab in patients with active lupus nephritis. By tracking these specific biomarkers, clinicians can gain a clearer indication of which individuals are on a trajectory toward renal recovery and which may require alternative therapeutic strategies.
References
1. Nagy S, Kesselman MM. The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review.. Cureus. 2024. doi:10.7759/cureus.76130
2. Sales GTM, Macedo NJ, Neto ETDR, Kirsztajn GM. Current treatment of lupus nephritis: an overview of the new guidelines.. Jornal brasileiro de nefrologia. 2025. doi:10.1590/2175-8239-JBN-2025-0092en
3. Joy A, Muralidharan A, Alfaraj M, Shantharam D, Cherukuri ASS, Muthukumar A. The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review.. Cureus. 2022. doi:10.7759/cureus.25887
4. Stolyar L, Lahita RG, Panush RS. Rituximab use as induction therapy for lupus nephritis: a systematic review.. Lupus. 2020. doi:10.1177/0961203320928412
5. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 2020. doi:10.1056/nejmoa2001180
6. Zhang H, Chen J, Zhang Y, Zhao N, Xu D. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.. Renal failure. 2023. doi:10.1080/0886022X.2023.2207671
7. Shrestha S, Budhathoki P, Adhikari Y, et al. Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis.. Cureus. 2021. doi:10.7759/cureus.20440
8. Lee YH, Song GG. Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a meta-analysis of randomized trials.. Zeitschrift fur Rheumatologie. 2026. doi:10.1007/s00393-025-01760-7
9. Nordmann-Gomes A, Cojuc-Konigsberg G, Hernández-Andrade A, et al. Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups.. Lupus science & medicine. 2024. doi:10.1136/lupus-2024-001331
